Skip to main content
. 2022 Jun 21;6:40. doi: 10.1038/s41698-022-00283-7

Table 1.

List of blood-based lncRNAs investigated as potential biomarkers for diagnosis of various cancers.

LncRNA Cancer type Source Sensitivity (%) Specificity (%) AUC / QUADAS Normalization Reference
MALAT-1 Nonsmall-cell lung cancer Blood cells 56 96 AUC 0.79 GAPDH 25
Nonsmall-cell lung cancer Whole blood N.A. N.A. AUC 0.718 GAPDH 51
Prostate cancer Plasma 58.6 84.8 AUC 0.836 Standard curve 26
Hepatocellular carcinoma Plasma 51.1 89.3 AUC 0.66 MALAT-1 48
LINC00152 Gastric cancer Plasma 48.1 85.2 AUC 0.675 GAPDH 19
Hepatocellular carcinoma Plasma N.A. N.A. AUC 0.85 5 S 43
Hepatocellular carcinoma Serum 78.3 89.2 AUC 0.877 GAPDH 44
UCA1 Hepatocellular carcinoma Serum 92.7 82.1 AUC 0.861 GAPDH 45
Hepatocellular carcinoma Serum 91.4 88.6 QUADAS 11 β-actin 46
Colorectal cancer Plasma N.A. N.A. N.A. Cel-miR-39 178
Gastric cancer Plasma N.A. N.A. AUC 0.928 GAPDH 104
Osteosarcoma Serum N.A. N.A. AUC 0.831 GAPDH 179
H19 Gastric cancer Plasma 74 58 AUC 0.64 LncRNA levels 17
Gastric cancer Plasma 82.9 72.9 AUC 0.838 Standard curve 38
Gastric cancer Plasma 68.75 56.67 AUC 0.724 GAPDH 60
Breast cancer Plasma 56.7 86.7 AUC 0.81 β-actin 39
PVT1 Cervical cancer Serum 71.6 98.8 AUC 0.932 GAPDH 176
Melanoma Serum 94.12 85.11 AUC 0.938 GAPDH 177
WRAP53 Hepatocellular carcinoma Serum 85.4 82.1 AUC 0.896 GAPDH 45
HULC Hepatocellular carcinoma Blood cells N.A. N.A. N.A. β-actin 27
Hepatocellular carcinoma Plasma N.A. N.A. N.A. GAPDH 28
Hepatocellular carcinoma Plasma N.A. N.A. AUC 0.78 5 S 43
Gastric cancer Plasma 58 80 AUC 0.65 GAPDH 30
HOTAIR Colorectal cancer Blood cells 67 92.5 AUC 0.87 PPIA 42
Cervical cancer Serum N.A. N.A. N.A. GAPDH 105
CTBP Hepatocellular carcinoma Serum 91 88.5 QUADAS 11 β-actin 46
GIHCG Renal cell carcinoma Serum 87 84.8 AUC 0.920 N.A. 34
Cervical cancer Serum 88.7 87.5 AUC 0.940 β-actin 90
PCA3 Prostate cancer Periph. Blood 32 94 N.A. N.A. 14
RP11-445H22.4 Breast cancer Serum 92 74 AUC 0.904 U6 40
uc003wbd Hepatocellular carcinoma Serum N.A. N.A. AUC 0.86 β-actin 49
AF085935 Hepatocellular carcinoma Serum N.A. N.A. AUC 0.96 β-actin 49
GACAT2 Gastric cancer Plasma 87 28 AUC 0.622 GAPDH 29
SPRY4-IT1 Hepatocellular carcinoma Plasma 87.3 50 QUADAS 12 18 S 47
uc001ncr Hepatocellular carcinoma Serum N.A. N.A. AUC 0.885 GAPDH 50
AX800134 Hepatocellular carcinoma Serum N.A. N.A. AUC 0.925 GAPDH 50
ZNFX1-AS1 Gastric cancer Plasma 84 68 AUC 0.85 GAPDH 30
LINC00152 + AFP Hepatocellular carcinoma Serum 85.3 83.4 AUC 0.906 GAPDH 44
XIST + HIF1A-AS1 Nonsmall-cell lung cancer Serum N.A. N.A. AUC 0.931 GAPDH 62
PVT1 + uc002mbe.2 Hepatocellular carcinoma Serum 60.5 90.6 QUADAS 11 GAPDH 64
GAS5 + SRA Pancreatic cancer (IPMN) Plasma 82 59 AUC 0.729 β-actin PGK1 PPIB 69
SPRY4-IT1 + ANRIL + NEAT1 Nonsmall-cell lung cancer Plasma 82.8 92.3 AUC 0.876 N.A. 61
LINC00152 + UCA1 + AFP Hepatocellular carcinoma Serum 82.9 88.2 AUC 0.912 GAPDH 44
CUDR (UCA1) + LSINCT-5 + PTENP1 Gastric cancer Serum 81.8 85.2 AUC 0.829 β-actin 41
SPRY4-IT1 + POU3F3 + HNF1A-AS1 Esophageal squamous cell carcinoma Plasma 72.8 89.4 AUC 0.842 GAPDH 63
XLOC_006844 + LOC152578 + XLOC_000303 Colorectal cancer Plasma 80 84 AUC 0.975 N.A. 65
RP11-160H22.5 + XLOC_014172 + LOC149086 Hepatocellular carcinoma Plasma 82 73 AUC 0.896 β-actin 3
UCA1 + POU3F3 ESCCAL-1 + PEG10 Esophageal squamous cell carcinoma Serum 80.2 80.2 AUC 0.853 GAPDH 66
LET + PVT1 + PANDAR + PTENP1 + linc00963 Renal cell carcinoma Serum 67.6 91.4 AUC 0.823 β-actin 68
AOC4P + BANCR + CCAT2 + LINC00857 + TINCR Gastric cancer Plasma 0.82 0.87 AUC 0.91 GAPDH 67

N.A. not available / data presented in graphical format in original report.

Information reported includes the name of lncRNA, cancer type, source of lncRNA, lncRNA specificity, lncRNA sensitivity, AUC (ROC) value (area under the ROC curve - receiver operating characteristic), QUADAS score, normalization method and literature reference.